Teva Pharmaceutical Industries (TEVA) Depreciation & Amortization (CF) (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $241.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 3.98% year-over-year to $241.0 million; the trailing twelve-month figure through Jun 2026 stood at $989.0 million (down 3.32% YoY), and the FY2025 full-year result was $1.0 billion, down 5.38% from the prior year.
• Depreciation & Amortization (CF) improved to $241.0 million in Q2 2026 per TEVA's latest filing, from $239.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $358.0 million in Q2 2022 and bottomed at $239.0 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $278.0 million across 5 years, with a median of $267.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) rose 17.38% in 2022, then slipped 16.2% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $306.0 million in 2022, then slipped by 13.07% to $266.0 million in 2023, then advanced by 1.13% to $269.0 million in 2024, then dropped by 3.35% to $260.0 million in 2025, then declined by 7.31% to $241.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $241.0 million, $239.0 million, and $260.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.